Results 161 to 170 of about 59,389 (246)

Characterization of the Direct and Indirect Inhibition of Apoptosis by Full-Length Recombinant Bcl-xL Monomers. [PDF]

open access: yesChembiochem
Elsner C   +6 more
europepmc   +1 more source

BCL-xL Is a Target Gene Regulated by Hypoxia-inducible Factor-1α [PDF]

open access: hybrid, 2009
Ni Chen   +9 more
openalex   +1 more source

Combined Neuroprotective Effects of N,N‐Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats

open access: yesJournal of Neurochemistry, Volume 170, Issue 2, February 2026.
The ventral root avulsion (VRA) model provides an excellent experimental paradigm for studying injuries at the Central/Peripheral Nervous Systems (CNS/PNS) interface. By physically disconnecting motoneurons (MNs) from the spinal cord surface, VRA induces profound cellular, molecular, and functional deficits with limited spontaneous recovery.
Paola Andrea Caro Aponte   +7 more
wiley   +1 more source

PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models. [PDF]

open access: yesJ Exp Clin Cancer Res
Valentini E   +15 more
europepmc   +1 more source

Biochemical and Physiological Effects of Galanin in Health and Disease

open access: yesThe FASEB Journal, Volume 40, Issue 2, 31 January 2026.
Galanin is a biologically active neuropeptide hormone that mediates its effects through three galanin receptors. Galanin signaling induces changes in glucose homeostasis amongst others and plays a dynamic role in the physiological health of many organ systems.
Patrick Mireles   +3 more
wiley   +1 more source

Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis. [PDF]

open access: yesBr J Cancer
Gupta K   +7 more
europepmc   +1 more source

Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma. [PDF]

open access: yesMol Cancer Ther
Xu Y   +15 more
europepmc   +1 more source

Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia. [PDF]

open access: yesPLoS One
Kamihara Y   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy